NCT00542919

A Study for Patients With Non-Hodgkin's Lymphomas

A Multicenter, Open-label, Noncomparative Study of Enzastaurin in Patients With Non-Hodgkin's Lymphomas

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 57 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

In this study, all patients will get investigational drug. There will be no comparator drug. This study will evaluate three tumor types: T-cell lymphoma, Indolent B-cell lymphoma, and Aggressive B-cell lymphoma. Each tumor type will include several tumor subtypes: * T-cell lymphoma: Peripheral and Cutaneous T-cell lymphoma (PTCL, CTCL) * Indolent B-cell lymphoma: Small lymphocytic lymphoma, follicular lymphoma (Gr 1 or 2) and marginal zone lymphoma * Aggressive B-cell lymphoma: Primary CNS lymphoma, follicular lymphoma (Gr 3a and 3b) and aggressive lymphoma with prior clinical history of indolent lymphoma.

Conditions

• T-Cell Lymphoma
• B-Cell Lymphoma

Interventions

Type	Name	Description
DRUG	enzastaurin	1125 mg loading dose then 500 mg, oral, daily until progressive disease

Timeline

• Start date: 2007-11-01
• Primary completion: 2010-03-01
• Completion: 2018-02-27
• First posted: 2007-10-12
• Last updated: 2020-10-19
• Results posted: 2020-10-19

Locations

14 sites across 5 countries: United States, Australia, Brazil, Mexico, Peru